公开(公告)号：US09062045B2

公开(公告)日：2015-06-23

申请号：US13613291

申请日：2012-09-13

Applicant: Chao Chen ,  Haibing Deng ,  Haibing Guo ,  Feng He ,  Lei Jiang ,  Fang Liang ,  Yuan Mi ,  Huixin Wan ,  Yao-Chang Xu ,  Hongping Yu ,  Ji Yue (Jeff) Zhang

Inventor： Chao Chen ,  Haibing Deng ,  Haibing Guo ,  Feng He ,  Lei Jiang ,  Fang Liang ,  Yuan Mi ,  Huixin Wan ,  Yao-Chang Xu ,  Hongping Yu ,  Ji Yue (Jeff) Zhang

IPC: A61K31/397 ,  C07D471/04 ,  C07D519/00 ,  A61K31/437 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/5513 ,  A61K45/06 ,  C07D491/107

CPC classification number: A61K31/551 ,  A61K31/437 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/5513 ,  A61K45/06 ,  C07D471/04 ,  C07D491/107 ,  C07D519/00

Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Abstract translation: 本发明涉及式（I）的化合物及其盐：其中取代基如说明书中所定义; 用于治疗人或动物体的式（I）化合物，特别是关于c-Met酪氨酸激酶介导的疾病或病症; 使用式（I）化合物制备用于治疗这些疾病的药物; 包含式（I）化合物，任选在组合配偶体存在下的药物组合物，以及制备式（I）化合物的方法。

公开(公告)号：US08748459B2

公开(公告)日：2014-06-10

申请号：US13363895

申请日：2012-02-01

Applicant: Michael Philip Cohen ,  Daniel Timothy Kohlman ,  Sidney Xi Liang ,  Frantz Victor ,  Yao-Chang Xu ,  Bai-Ping Ying ,  DeAnna Piatt Zacherl ,  Deyi Zhang

Inventor： Michael Philip Cohen ,  Daniel Timothy Kohlman ,  Sidney Xi Liang ,  Frantz Victor ,  Yao-Chang Xu ,  Bai-Ping Ying ,  DeAnna Piatt Zacherl ,  Deyi Zhang

IPC: A61K31/445 ,  C07D401/06

CPC classification number: C07D401/06 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HTlF receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的酸加成盐，其中： R 1是C 1 -C 6烷基，取代的C 1 -C 6烷基，C 3 -C 7环烷基，取代的C 3 -C 7环烷基，C 3 -C 7环烷基-C 1 -C 3烷基，取代的C 3 -C 7环烷基-C 1 -C 3烷基，苯基，取代的苯基， 杂环或取代的杂环; R 2是氢，C 1 -C 3烷基，C 3 -C 6环烷基-C 1 -C 3烷基或式II的基团R 3是氢或C 1 -C 3烷基; R4是氢，卤素或C1-C3烷基; R5是氢或C1-C3烷基; R6是氢或C1-C6烷基; n为1〜6的整数。 本发明的化合物可用于激活5-HT1F受体，抑制神经元蛋白质外渗，以及用于治疗或预防哺乳动物偏头痛。 本发明还涉及合成式I化合物中的中间体的方法。

公开(公告)号：US08511424B2

公开(公告)日：2013-08-20

申请号：US13314963

申请日：2011-12-08

Applicant: Xiaolei Shirley Ao ,  Jin Chang Xu ,  John Albert Umina

Inventor： Xiaolei Shirley Ao ,  Jin Chang Xu ,  John Albert Umina

IPC: G10K11/00

CPC classification number: G10K11/00 ,  G01F23/2962 ,  G01N9/24 ,  G01N29/024 ,  G01N29/2462 ,  G01N2291/02818

Abstract: Acoustic waveguides are disclosed for mounting to a conduit. The acoustic waveguides provide a mounting area that minimizes the effect of the mount on the acoustic wave traveling through the waveguide while providing an effective seal, even under high pressure conditions.

Abstract translation: 公开了用于安装到导管的声波导。 声波导提供了一种安装区域，即使在高压条件下也能提供有效的密封，使安装件对穿过波导管的声波的影响最小化。

公开(公告)号：US20120329820A1

公开(公告)日：2012-12-27

申请号：US13363895

申请日：2012-02-01

Applicant: Michael P. Cohen ,  Daniel T. Kohlman ,  Sidney X. Liang ,  Frantz Victor ,  Yao-Chang Xu ,  Bai-Ping Ying ,  Deanna P. Zacherl ,  Deyi Zhang

Inventor： Michael P. Cohen ,  Daniel T. Kohlman ,  Sidney X. Liang ,  Frantz Victor ,  Yao-Chang Xu ,  Bai-Ping Ying ,  Deanna P. Zacherl ,  Deyi Zhang

IPC: A61K31/4545 ,  C07D409/14 ,  A61K31/506 ,  C07D405/14 ,  C07D417/14 ,  A61P25/06 ,  C07D401/06 ,  C07D401/14

CPC classification number: C07D401/06 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的酸加成盐，其中： R 1是C 1 -C 6烷基，取代的C 1 -C 6烷基，C 3 -C 7环烷基，取代的C 3 -C 7环烷基，C 3 -C 7环烷基-C 1 -C 3烷基，取代的C 3 -C 7环烷基-C 1 -C 3烷基，苯基，取代的苯基， 杂环或取代的杂环; R 2是氢，C 1 -C 3烷基，C 3 -C 6环烷基-C 1 -C 3烷基或式II的基团R 3是氢或C 1 -C 3烷基; R4是氢，卤素或C1-C3烷基; R5是氢或C1-C3烷基; R6是氢或C1-C6烷基; n为1〜6的整数。 本发明的化合物可用于激活5-HT1F受体，抑制神经元蛋白质外渗，以及治疗或预防哺乳动物偏头痛。 本发明还涉及合成式I化合物中的中间体的方法。

公开(公告)号：US20090209563A1

公开(公告)日：2009-08-20

申请号：US12221919

申请日：2008-08-07

Applicant: Michael Philip Cohen ,  Daniel Timothy Kohlman ,  Sidney Xi Liang ,  Vincent Mancuso ,  Yao-Chang Xu

Inventor： Michael Philip Cohen ,  Daniel Timothy Kohlman ,  Sidney Xi Liang ,  Vincent Mancuso ,  Yao-Chang Xu

IPC: A61K31/4545 ,  C07D401/06 ,  C07D409/14 ,  C07D405/14 ,  C07D401/14 ,  C07D417/14 ,  A61K31/506 ,  A61P25/06

CPC classification number: C07D401/06 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

Abstract translation: 本发明涉及式I化合物或其药学上可接受的酸加成盐，其中： R 1是C 1 -C 6烷基，取代的C 1 -C 6烷基，C 3 -C 7环烷基，取代的C 3 -C 7环烷基，C 3 -C 7环烷基-C 1 -C 3烷基，取代的C 3 -C 7环烷基-C 1 -C 3烷基，苯基，取代的苯基， 杂环或取代的杂环; R 2是氢，C 1 -C 3烷基，C 3 -C 6环烷基-C 1 -C 3烷基或式II的基团R 3是氢或C 1 -C 3烷基; R4是氢，卤素或C1-C3烷基; R5是氢或C1-C3烷基; R6是氢或C1-C6烷基; n为1〜6的整数。 本发明的化合物可用于激活5-HT1F受体，抑制神经元蛋白质外渗，以及治疗或预防哺乳动物偏头痛。 本发明还涉及合成式I化合物中的中间体的方法。

公开(公告)号：US07291632B2

公开(公告)日：2007-11-06

申请号：US10569109

申请日：2004-09-03

Applicant: Maria-Jesus Blanco-Pillado ,  Michael Philip Cohen ,  Sandra Ann Filla ,  Kevin John Hudziak ,  Daniel Timothy Kohlman ,  Dana Rae Benesh ,  Frantz Victor ,  Yao-Chang Xu ,  Bai-Ping Ying ,  DeAnna Piatt Zacherl ,  Deyi Zhang ,  Brian Michael Mathes

Inventor： Maria-Jesus Blanco-Pillado ,  Michael Philip Cohen ,  Sandra Ann Filla ,  Kevin John Hudziak ,  Daniel Timothy Kohlman ,  Dana Rae Benesh ,  Frantz Victor ,  Yao-Chang Xu ,  Bai-Ping Ying ,  DeAnna Piatt Zacherl ,  Deyi Zhang ,  Brian Michael Mathes

IPC: A61K31/445 ,  C07D211/32 ,  C07D211/72 ,  C07D421/00

CPC classification number: C07D211/58 ,  A61K31/4468 ,  A61K31/4523 ,  C04B35/632 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14

Abstract: The present invention relates to compounds of formula I: (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R3c═ or N═; R1 is C2–C6 alkyl, substituted C2–C6 alkyl, C3–C7 cycloalkyl, substituted C3–C7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1–C3 n-alkyl, C3–C6 cycloalkyl-C1–C3 alkyl, or a group of formula II (II) provided that when R1 is C2–C6 alkyl or substituted C2–C6 alkyl, R2 is hydrogen or methyl; R3a, R3b, and, when X is C(R3c)═, R3c, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R3a, R3b, and R3c may be other than hydrogen; R4 is hydrogen or C1–C3 alkyl; R5 is hydrogen, C1–C3 alkyl, or C3–C6 cycloalkylcarbonyl, provided that when R3a is other than hydrogen, R5 is hydrogen; R6 is hydrogen or C1–C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.

公开(公告)号：US07286990B1

公开(公告)日：2007-10-23

申请号：US09889911

申请日：2000-01-21

Applicant: Paul Edmonds ,  Yi Zhang ,  George Sollman ,  Michael P. Tel ,  Chang Xu ,  Priyen Doshi ,  Stephen Co ,  David Weinstein ,  Andy Chan

Inventor： Paul Edmonds ,  Yi Zhang ,  George Sollman ,  Michael P. Tel ,  Chang Xu ,  Priyen Doshi ,  Stephen Co ,  David Weinstein ,  Andy Chan

IPC: G10L21/06

CPC classification number: H04M3/4938 ,  H04M2203/2072 ,  H04M2203/4509

Abstract: An interface for accessing data from one or more information systems using a wireless telephone or other user device. The interface is presented to a user as an abstraction of a unified mailbox and permits access by the user to messaging and other services from the wireless device. The interface is coupled to one or more converting modules to convert user inputs from the format in which they are received into a format that may be input to the desired information system.

Abstract translation: 用于使用无线电话或其他用户设备从一个或多个信息系统访问数据的接口。 该接口作为统一邮箱的抽象呈现给用户，并允许用户从无线设备访问消息传递和其他服务。 接口耦合到一个或多个转换模块，以将用户输入从其接收的格式转换成可输入到期望的信息系统的格式。

公开(公告)号：US20060287363A1

公开(公告)日：2006-12-21

申请号：US10569109

申请日：2004-09-03

Applicant: Maria-Jesus Blanco-Pillado ,  Michael Cohen ,  Sandra Filla ,  Kevin Hudzlak ,  Daniel Kohlman ,  Dana Benesh ,  Frantz Victor ,  Yao-Chang Xu ,  Bai-Ping Ying ,  DeAnna Zacherl ,  Deyi Zhang ,  Brian Mathes

Inventor： Maria-Jesus Blanco-Pillado ,  Michael Cohen ,  Sandra Filla ,  Kevin Hudzlak ,  Daniel Kohlman ,  Dana Benesh ,  Frantz Victor ,  Yao-Chang Xu ,  Bai-Ping Ying ,  DeAnna Zacherl ,  Deyi Zhang ,  Brian Mathes

IPC: A61K31/4545 ,  A61K31/454 ,  C07D403/14

CPC classification number: C07D211/58 ,  A61K31/4468 ,  A61K31/4523 ,  C04B35/632 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14

Abstract: The present invention relates to compounds of formula I: (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R3c═ or N═; R1 is C2-C6 alkyl, substituted C2-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 n-alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II (II) provided that when R1 is C2-C6 alkyl or substituted C2-C6 alkyl, R2 is hydrogen or methyl; R3a, R3b, and, when X is C(R3c)═, R3c, are each independently hydrogen, fluoro, or methyl, provided that no more than one of R3a, R3b, and R3c may be other than hydrogen; R4 is hydrogen or C1-C3 alkyl; R5 is hydrogen, C1-C3 alkyl, or C3-C6 cycloalkylcarbonyl, provided that when R3a is other than hydrogen, R5 is hydrogen; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal.

公开(公告)号：US20060211734A1

公开(公告)日：2006-09-21

申请号：US10552131

申请日：2004-04-14

Applicant: Maria-Jesus Blanco-Pillado ,  Dana Benesh ,  Sandra Filla ,  Kevin Hudziak ,  Brian Mathes ,  Daniel Kohlman ,  Bai-Ping Ying ,  Deyl Zhang ,  Yao-Chang Xu

Inventor： Maria-Jesus Blanco-Pillado ,  Dana Benesh ,  Sandra Filla ,  Kevin Hudziak ,  Brian Mathes ,  Daniel Kohlman ,  Bai-Ping Ying ,  Deyl Zhang ,  Yao-Chang Xu

IPC: A61K31/4545 ,  A61K31/454 ,  C07D401/14 ,  C07D403/14

CPC classification number: C07D401/12 ,  C07D211/44 ,  C07D211/46 ,  C07D211/54 ,  C07D401/14 ,  C07D409/12 ,  C07D409/14

Abstract: The present invention relates to compounds of formula 1: and pharmaceutically acceptable acid addition sails thereof. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or preverition of migraine in mammals, particularly humans.

Abstract translation: 本发明涉及式1的化合物及其药学上可接受的酸加成口。 本发明的化合物可用于激活5-HT 1F受体，抑制神经元蛋白质外渗，以及在哺乳动物，特别是人中治疗或预防偏头痛。

公开(公告)号：US20050282817A1

公开(公告)日：2005-12-22

申请号：US11184522

申请日：2005-07-19

Applicant: Alexander Godfrey ,  Daniel Kohlman ,  John O'Toole ,  Yao-Chang Xu ,  Tony Zhang

Inventor： Alexander Godfrey ,  Daniel Kohlman ,  John O'Toole ,  Yao-Chang Xu ,  Tony Zhang

IPC: C07D295/08 ,  A61K20060101 ,  A61K31/395 ,  A61K31/495 ,  A61K31/496 ,  A61P1/00 ,  A61P3/04 ,  A61P9/00 ,  A61P15/10 ,  A61P25/00 ,  A61P25/06 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  A61P25/34 ,  A61P43/00 ,  C07C20060101 ,  C07C45/00 ,  C07C45/29 ,  C07C45/40 ,  C07C45/51 ,  C07C45/59 ,  C07C45/68 ,  C07C49/355 ,  C07C49/563 ,  C07C49/577 ,  C07C49/583 ,  C07C49/86 ,  C07D20060101 ,  C07D213/74 ,  C07D295/04 ,  C07D295/088 ,  C07D295/092 ,  C07D295/10 ,  C07D295/104 ,  C07D295/108 ,  C07D401/04 ,  C07D521/00

CPC classification number: C07D295/088 ,  A61K31/495 ,  A61K31/496 ,  C07C45/004 ,  C07C45/29 ,  C07C45/40 ,  C07C45/515 ,  C07C45/59 ,  C07C45/68 ,  C07C49/563 ,  C07C49/577 ,  C07C49/583 ,  C07C49/86 ,  C07D213/74 ,  C07D295/104 ,  C07D295/108

Abstract: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.